Browsing Tag
Avacta Group
5 posts
Avacta (AIM: AVCT) investor roadmap: The milestones that matter between now and the AVA6103 data readout in late 2026
Avacta (AVCT) faces two clinical data readouts in 2026. This investor roadmap maps every milestone, risk, and signal to watch through the AVA6103 Phase 1 readout.
April 1, 2026
AVCT near 52-week high as Avacta doses first patient in AVA6103 Phase 1 trial
Avacta (AVCT) has treated the first patient in the FOCUS-01 Phase 1 trial of AVA6103, its Gen Two pre|CISION exatecan PDC. Initial data expected late 2026. Read more.
March 31, 2026
Avacta Group (AIM: AVCT) closes oversubscribed £10m placing at 9.35% discount as AVA6103 enters clinical dosing
Avacta Group (AIM: AVCT) completes an oversubscribed £10m equity placing at 63p ahead of late-2026 AVA6103 Phase 1 data. Read the full analyst breakdown.
March 27, 2026
Avacta Group reports promising early results for Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leading life sciences company dedicated to developing innovative oncology drugs and powerful…
March 23, 2024
Avacta Group progresses to final cohort in Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leader in the life sciences sector specializing in innovative oncology drugs and…
September 19, 2023